Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Stewart

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Therapeutic Drug Monitoring|January 1, 1982
A randomized-blinded evaluation of analytical error associated with the enzyme immunoassay (EMIT) of gentamicinC F Stewart, E T Melton, J Karas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1995
Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenograftsJ A Houghton, P J Cheshire, C L Morton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1990
Changes in the clearance of total and unbound etoposide in patients with liver dysfunctionC F Stewart, S G Arbuck, R A Fleming, et al.
Urologic Oncology|January 13, 2011
Successful treatment of metastatic choriocarcinoma after DMP 840C B Pratt, B N Rao, C F Stewart, et al.
Journal of Pharmaceutical Sciences|March 1, 1992
Factors affecting in vitro protein binding of etoposide in humansR A Fleming, W E Evans, S G Arbuck, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in miceC F Stewart, W C Zamboni, W R Crom, et al.
Clinical Pharmacology and Therapeutics|January 1, 1989
Altered protein binding of etoposide in patients with cancerC F Stewart, J A Pieper, S G Arbuck, et al.
Cancer|September 15, 1991
Disposition of high-dose methotrexate in an obese cancer patientR A Fleming, R M Eldridge, C E Johnson, et al.
Clinical Pharmacology and Therapeutics|October 1, 1991
Relation of systemic exposure to unbound etoposide and hematologic toxicityC F Stewart, S G Arbuck, R A Fleming, et al.
Clinical Pharmacology and Therapeutics|April 1, 1990
Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritisC F Stewart, R A Fleming, C R Arkin, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Therapeutic Drug Monitoring|January 1, 1982
A randomized-blinded evaluation of analytical error associated with the enzyme immunoassay (EMIT) of gentamicinC F Stewart, E T Melton, J Karas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1995
Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenograftsJ A Houghton, P J Cheshire, C L Morton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1990
Changes in the clearance of total and unbound etoposide in patients with liver dysfunctionC F Stewart, S G Arbuck, R A Fleming, et al.
Urologic Oncology|January 13, 2011
Successful treatment of metastatic choriocarcinoma after DMP 840C B Pratt, B N Rao, C F Stewart, et al.
Journal of Pharmaceutical Sciences|March 1, 1992
Factors affecting in vitro protein binding of etoposide in humansR A Fleming, W E Evans, S G Arbuck, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in miceC F Stewart, W C Zamboni, W R Crom, et al.
Clinical Pharmacology and Therapeutics|January 1, 1989
Altered protein binding of etoposide in patients with cancerC F Stewart, J A Pieper, S G Arbuck, et al.
Cancer|September 15, 1991
Disposition of high-dose methotrexate in an obese cancer patientR A Fleming, R M Eldridge, C E Johnson, et al.
Clinical Pharmacology and Therapeutics|October 1, 1991
Relation of systemic exposure to unbound etoposide and hematologic toxicityC F Stewart, S G Arbuck, R A Fleming, et al.
Clinical Pharmacology and Therapeutics|April 1, 1990
Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritisC F Stewart, R A Fleming, C R Arkin, et al.
Pageof 10